Skip to main content
. 2020 Nov 11;8(2):e001467. doi: 10.1136/jitc-2020-001467

Table 2.

Associations of CD73 expression with baseline characteristics of patients (N=138)

Baseline characteristics (N) CD73 expression P value*
Positive (N=42) Negative (N=96)
High (n=22) Low (n=20)
n % n % n %
Metastatic status at presentation 0.002
 Localized RCC (n=107) 13 12 12 11 82 77
 De novo mRCC (n=31) 9 29 8 26 14 45
Histology 0.11†
 ccRCC (n=103) 13 13 15 15 75 73
 nccRCC (n=33) 8 24 5 15 20 61
 Papillary (n=16) 6 38 5 31 5 31
 Chromophobe (n=14) 2 14 . . 12 86
 RCC unclassified (n=3) . . . . 3 100
 Unknown (n=2) 1 50 1 50
Sarcomatoid features <0.0001
 No (n=124) 15 12 15 12 94 76
 Yes (n=10) 5 50 4 40 1 10
 Unknown (n=4) 2 50 1 25 1 25
Fuhrman nuclear grade 0.035
 G1-2 (n=75) 11 15 7 9 57 76
 G3 (n=38) 5 13 8 21 25 66
 G4 (n=22) 6 27 5 23 11 50
 Unknown (n=3) 3 100
Pathological T stage 0.004
 T1 (n=60) 7 12 2 3 51 85
 T2 (n=28) 5 19 7 25 16 57
 T3-4 (n=46) 10 22 9 20 27 59
 Unknown (n=4) 2 50 2 50
AJCC stage <0.0001
 I (n=57) 5 9 2 4 50 88
 II (n=19) 4 21 4 21 11 58
 III (n=26) 3 12 4 15 19 73
 IV (n=34) 10 29 9 27 15 44
 Unknown (n=2) 1 50 1 50

*Cochran-Armitage Trend test (for variables with two categories) and Jonckheere-Terpstra test (for variables with ≥3 ordered categories); unknown group was excluded from the comparison.

†P value is for comparison of ccRCC versus nccRCC.

AJCC, American Joint Committee on Cancer; ccRCC, clear cell renal cell carcinoma; mRCC, metastatic renal cell carcinoma; nccRCC, non-clear cell renal cell carcinoma; RCC, renal cell carcinoma.